Home World News Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced... World News Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC By Ogkologos - April 13, 2026 329 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR ASCO Annual Meeting 2023: Adding Durvalumab and Olaparib to Treatment Delays... June 3, 2023 ViPOR Regimen Associated with Durable Remissions in Patients with Specific Molecular... August 7, 2024 ESMO Breast Cancer 2025, Munich, Germany, 14-17 May 2025 May 7, 2025 Qué deben saber los latinos sobre dejar de fumar y las... November 19, 2021 Load more HOT NEWS Studying Molecular Subtypes of Peritoneal Metastases in Gastric Cancer Aggressive Prostate Cancer Subtype More Common Than Expected No Clinical Benefit from Nivolumab Plus Ipilimumab Over Nivolumab Alone as... Cancer Survivor And His Organ Donor Run NYC Marathon Together To...
